Asciminib in Newly Diagnosed CML | NEJM
Research comparing the efficacy and safety of the BCR::ABL1 inhibitor asciminib with investigator-selected tyrosine kinase inhibitors in patients with newly diagnosed chronic myeloid leukemia is summarized in a new Quick Take video.
To see the full article, follow this link: https://nej.md/4bNNr3c
#hematology #oncology #clinicaltrials #nejm
